A 28-Day Study of the Effect of Coated VICRYL* Plus Antibacterial Suture (Coated Polyglactin 910 Suture with Triclosan) on Wound Healing in Guinea Pig Linear Incisional Skin Wounds

The effect of triclosan-coated sutures on the incidence of surgical site infection in laparoscopic sleeve gastrectomy, laparoscopic appendicectomy or laparoscopic cholecystectomy: A multi-centre, double-blind, randomized, intra-individual study

Surgical site infection (SSI) is a common cause of post-operative morbidity. According to the latest report announced by CDC, the SSI accounts for 20% of healthcare-associated infection with a high risk of mortality up to twofold to 11-fold increase with high economic burden for the prolonged hospital stay. Port site infection (PSI) is a subgroup of SSI occurring at the ports of laparoscopy. We tried to determine the efficacy of polyglactin 910 suture coated with triclosan in lowering the rate of PSI in some of the clean-contaminated wound surgeries. This study included 480 individuals eligible for laparoscopic cholecystectomy, appendicectomy or sleeve operations. Polyglactin 910 sutures coated with triclosan were used in one port site incision while polyglactin 910 sutures were used in the other port sites incisions. In patients who underwent laparoscopic cholecystectomy and appendicectomy, the incidence of PSI was significantly lower in the triclosan-coated sutures. In sleeve gastrectomy patients, although a lower number of triclosan-coated sutures developed PSI, there was no statistically significant difference between triclosan and non-triclosan-coated sutures. This study showed that using sutures coated with antiseptics like triclosan has clinical benefits to prevent SSIs in most of the laparoscopic surgeries.

[Comparison of wound infection rates after colon and rectal surgeries using triclosan-coated or bare sutures -- a multi-center, randomized clinical study]

BACKGROUND

Surgical Site Infection (SSI) is the third most frequent nosocomial infection, and accounts for 14-16% of all infections. While the treatment of SSI can be very costly, previous results indicated that triclosan may reduce SSI rate. Therefore, we carried out a prospective randomised trial to further evaluate the effect of triclosan after elective colorectal surgery.

METHODS

Seven surgical units in Hungary were involved in a prospective, randomised, multicentric clinical trial to compare triclosan coated (PDS plus®) and uncoated (PDS II®) sutures for abdominal wall closure in elective colorectal surgery. Pre- and perioperative variables were recorded in an online database. The primary aims of the study were to determine the incidence of SSI and the pathogens associated with it, as well as evaluation of additional cost of treatment.

RESULTS

485 patients were randomised. SSI occurred in 47 cases (12.5%), of those 23 (12.23%) from the triclosan group (n = 188) and 24 (12.18%) from the uncoated group (n = 197, p = 0.982). In 13 (27.66%) cases late appearance of SSI was detected, of those 4 patients with triclosan coated suture (8.51%) and 9 patients with uncoated suture (19.15%, p = 0.041). There was no difference between the type of incisions or elective colon and rectal resections in terms of incidence of SSI.

CONCLUSION

Beneficial effect of triclosan against Gram positive bacteria could not be confirmed in our study due to the relatively low number of patients with SSI. Furthermore, triclosan did not influence the incidence of SSI due to Gram negative bacteria. SSI rate decreased by 50% compared to our previous study, however, it was regardless of the use of coated or uncoated PDS loop. Finally, operative factors were more important than patient's risk factors in terms of incidence of SSI. In case SSI developed, delayed discharge from hospital as well as special wound care significantly increased overall cost of treatment.

In-vitro activity of triclosan-eluting ureteral stents against common bacterial uropathogens

BACKGROUND AND PURPOSE

Ureteral stents are commonly used in urology today, but the biofilms that form on them within hours of placement may harbor bacteria that can result in infection or encrustation. Triclosan is an antimicrobial commonly used in consumer and medical products that inhibits bacterial fatty-acid synthesis. The bactericidal and bacteriostatic effect of a triclosan-eluting ureteral stent was tested against clinical isolates of common bacterial uropathogens in an in-vitro setting.

MATERIALS AND METHODS

Triclosan eluted from a drug-loaded ureteral stent was suspended in artificial urine with bacterial pathogens (Escherichia coli C1214, Proteus mirabilis 296, Enterococcus faecalis 1131, Klebsiella pneumoniae 280, Staphylococcus aureus Newman, Pseudomonas aeruginosa AK1) to assess growth, virulence-promoter activity, and bacterial adherence to the stent. Generic stents were utilized as controls.

RESULTS

Triclosan inhibited the growth of E. faecalis, K. pneumoniae, S. aureus, and P. mirabilis in a dose-dependent manner. Pseudomonas aeruginosa demonstrated significant resistance. Lower concentrations of triclosan downregulated E. coli virulence-factor promoters of outer membrane protein X and p-fimbriae. Triclosan stents had significantly fewer adherent viable bacteria than control stents.

CONCLUSIONS

Triclosan-eluting ureteral stents inhibit the growth of common bacterial uropathogens and thus may reduce the incidence of urinary-tract infections and, potentially, encrustation. This drug-eluting stent provides both mechanical drainage of the upper urinary tract and local antibiosis.

Development of a porcine incisional wound model and novel scarring scales

A major goal of wound management is to reduce scarring. Prior to evaluating novel anti-scarring therapies, we developed a porcine incisional wound model and scarring outcome measures. Forty-eight full-thickness incisions (3 cm in length) and excisional wounds (3 x 0.5 cm) were created on two animals and closed with sutures (n=24) or tissue adhesive (n=24). Scars were evaluated using two validated clinical scar scales and a novel scale developed for animals. Full-thickness biopsies were obtained at 5 and 8 weeks for determination of scar morphology using H&E and Congo red staining with and without polarized light. Scar tissue was classified based on the collagen fiber morphology and "redness" ratio, which is a measure of the relative distribution of collagen fiber in all three spatial dimensions. The clinical cosmetic scales were highly reliable, yet nondiscriminatory. The novel gross cosmetic and histomorphological scores were both highly reliable (0.75 and 0.70, respectively), yet poorly correlated with each other (0.17). The "redness" ratio and cross-sectional surface area measurements were also highly reliable (r=0.96 and 0.99, respectively) but unrelated to cosmetic outcomes. However, the "redness ratio" did correlate with the histomorphologic appearance of the scars, with poorer appearing clinical scars receiving lower ratios (ANOVA p=0.001). Significant differences in cosmetic scores were noted between excisional and incisional wounds favoring incisions (p=0.0019). We describe a novel porcine model for incisional and excisional wounds. The new clinical and histomorphologic outcomes were highly reliable yet poorly correlated. In general, incisional wounds healed with less apparent scarring than excisional wounds.

Intraoperative handling and wound healing: controlled clinical trial comparing coated VICRYL plus antibacterial suture (coated polyglactin 910 suture with triclosan) with coated VICRYL suture (coated polyglactin 910 suture)

BACKGROUND

Coated polyglactin 910 suture with triclosan was developed recently in order to imbue the parent suture, coated polyglactin 910, with antibacterial activity against the most common organisms that cause surgical site infections (SSI). Because such alterations could alter the physical properties of the suture, this study sought to compare the intraoperative handling and wound healing characteristics of coated polyglactin 910 suture with triclosan and traditional coated polyglactin 910 suture in pediatric patients undergoing various general surgical procedures.

METHODS

This was a prospective, randomized, controlled, open-label, comparative, single-center study. Pediatric patients (age 1-18 years) undergoing various surgical procedures were randomized in a 2:1 ratio to treatment with either coated polyglactin 910 suture with triclosan or coated polyglactin 910 suture. The primary endpoint was the surgeon's assessment of the overall intraoperative handling of coated polyglactin 910 suture with triclosan and traditional coated polyglactin 910 suture without triclosan. The secondary endpoints included specific intraoperative suture handling measures and wound healing assessments. The suture handling measures were (1) ease of passage through tissue; (2) first-throw knot holding; (3) knot tie-down smoothness; (4) knot security; (5) surgical handling; (6) surgical hand; (7) memory; and (8) suture fraying. Assessment of wound healing included the following: Healing progress, infection, edema, erythema, skin temperature, seroma, suture sinus, and pain. Adverse events were recorded.

RESULTS

Scores for intraoperative handling were favorable and not significantly different for both sutures, although coated polyglactin 910 suture with triclosan received more "excellent" scores (71% vs. 59%). Wound healing characteristics were comparable for both sutures except for pain on postoperative day 1. Significantly fewer patients treated with polyglactin 910 suture with triclosan reported pain on day 1 than patients who received the other suture (68% vs. 89%, p = 0.01). The overall incidence of adverse events was 18%; none was devicerelated.

CONCLUSIONS

Coated polyglactin 910 suture with triclosan performed as well or better than traditional coated polyglactin 910 suture in pediatric patients undergoing general surgical procedures. The incidence of postoperative pain was significantly less in patients treated with coated polyglactin 910 suture with triclosan than the traditional suture. We speculate that polyglactin 910 suture with triclosan, by inhibiting bacterial colonization of the suture, reduced pain that can be an indicator of "subclinical" infection. Coated polyglactin 910 suture with triclosan may be a useful alternative in patients at increased risk of developing SSI.